Cost effectiveness review of text messaging, smartphone application, and website interventions targeting T2DM or hypertension.
Journal
NPJ digital medicine
ISSN: 2398-6352
Titre abrégé: NPJ Digit Med
Pays: England
ID NLM: 101731738
Informations de publication
Date de publication:
18 Aug 2023
18 Aug 2023
Historique:
received:
27
02
2023
accepted:
07
07
2023
medline:
19
8
2023
pubmed:
19
8
2023
entrez:
18
8
2023
Statut:
epublish
Résumé
Digital health interventions have been shown to be clinically-effective for type 2 diabetes mellitus (T2DM) and hypertension prevention and treatment. This study synthesizes and compares the cost-effectiveness of text-messaging, smartphone application, and websites by searching CINAHL, Cochrane Central, Embase, Medline and PsycInfo for full economic or cost-minimisation studies of digital health interventions in adults with or at risk of T2DM and/or hypertension. Costs and health effects are synthesised narratively. Study quality appraisal using the Consensus on Health Economic Criteria (CHEC) list results in recommendations for future health economic evaluations of digital health interventions. Of 3056 records identified, 14 studies are included (7 studies applied text-messaging, 4 employed smartphone applications, and 5 used websites). Ten studies are cost-utility analyses: incremental cost-utility ratios (ICUR) vary from dominant to €75,233/quality-adjusted life year (QALY), with a median of €3840/QALY (interquartile range €16,179). One study finds no QALY difference. None of the three digital health intervention modes is associated with substantially better cost-effectiveness. Interventions are consistently cost-effective in populations with (pre)T2DM but not in populations with hypertension. Mean quality score is 63.0% (standard deviation 13.7%). Substandard application of time horizon, sensitivity analysis, and subgroup analysis next to transparency concerns (regarding competing alternatives, perspective, and costing) downgrades quality of evidence. In conclusion, smartphone application, text-messaging, and website-based interventions are cost-effective without substantial differences between the different delivery modes. Future health economic studies should increase transparency, conduct sufficient sensitivity analyses, and appraise the ICUR more critically in light of a reasoned willingness-to-pay threshold.Registration: PROSPERO (CRD42021247845).
Identifiants
pubmed: 37596488
doi: 10.1038/s41746-023-00876-x
pii: 10.1038/s41746-023-00876-x
pmc: PMC10439143
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
150Subventions
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 945246
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 945246
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 945246
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 945246
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 945246
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 945246
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : APP2007006
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : APP2007006
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : APP2007006
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : APP2007006
Investigateurs
Natalya Usheva
(N)
Violeta Iotova
(V)
Andreas Triantafyllidis
(A)
Konstantinos Votis
(K)
Florian Toti
(F)
Konstantinos Makrilakis
(K)
Chiara Seghieri
(C)
Luis Moreno
(L)
Sabine Dupont
(S)
Leo Lewis
(L)
Djordje Djokic
(D)
Helen Skouteris
(H)
Informations de copyright
© 2023. Springer Nature Limited.
Références
Value Health. 2015 Mar;18(2):161-72
pubmed: 25773551
Am J Hypertens. 2020 Mar 13;33(3):252-260
pubmed: 31711220
Physiol Behav. 2020 Mar 1;215:112786
pubmed: 31863856
Lancet. 2019 Aug 24;394(10199):611
pubmed: 31448722
Nat Rev Cardiol. 2015 May;12(5):289-300
pubmed: 25687779
JAMA Netw Open. 2021 Sep 1;4(9):e2122559
pubmed: 34519769
BMJ Open. 2017 Nov 15;7(11):e017184
pubmed: 29146638
J Med Internet Res. 2020 Sep 17;22(9):e16053
pubmed: 32940613
Intern Emerg Med. 2020 Mar;15(2):241-250
pubmed: 31321709
Medicine (Baltimore). 2014 Dec;93(28):e312
pubmed: 25526482
Bull World Health Organ. 2016 Dec 1;94(12):925-930
pubmed: 27994285
Hypertension. 2001 Apr;37(4):1053-9
pubmed: 11304502
Pharmacoeconomics. 2013 Dec;31(12):1087-90
pubmed: 24202991
Prev Med. 2021 Dec;153:106722
pubmed: 34271077
JMIR Mhealth Uhealth. 2020 Apr 28;8(4):e15400
pubmed: 32343253
Diabetologia. 2013 Jul;56(7):1489-93
pubmed: 23584433
JAMA. 2021 Aug 24;326(8):717-727
pubmed: 34427600
J Am Med Inform Assoc. 2020 Jun 1;27(6):939-945
pubmed: 32357368
PLoS One. 2017 Feb 2;12(2):e0170581
pubmed: 28152012
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
JAMA Pediatr. 2019 Dec 1;173(12):1154-1163
pubmed: 31589252
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Value Health Reg Issues. 2019 Dec;20:41-46
pubmed: 30856542
Lancet Digit Health. 2023 Mar;5(3):e144-e159
pubmed: 36828607
PLoS One. 2016 Oct 5;11(10):e0163627
pubmed: 27706216
Value Health. 2018 Dec;21(12):1357-1364
pubmed: 30502778
Lancet Digit Health. 2023 Mar;5(3):e125-e143
pubmed: 36828606
Ann Intern Med. 2015 Sep 15;163(6):452-60
pubmed: 26167962
NPJ Digit Med. 2021 Jul 22;4(1):114
pubmed: 34294852
J Diabetes Sci Technol. 2023 May;17(3):715-726
pubmed: 34986658
Int J Endocrinol. 2021 Jul 01;2021:8827629
pubmed: 34306072
Ther Adv Chronic Dis. 2021 Sep 08;12:20406223211042542
pubmed: 34729144
J Diabetes Res. 2016;2016:2159890
pubmed: 26885527
JAMA. 2013 Dec 11;310(22):2395-6
pubmed: 24158428
Pharmacoecon Open. 2023 Mar;7(2):163-173
pubmed: 36495462
Nat Rev Nephrol. 2020 Apr;16(4):223-237
pubmed: 32024986
J Med Internet Res. 2020 Sep 29;22(9):e20283
pubmed: 32990635
Eur J Intern Med. 2016 Jan;27:37-47
pubmed: 26655787
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
Lancet. 2021 Sep 18;398(10305):1023-1025
pubmed: 34461041
J Diabetes Res. 2016;2016:1219581
pubmed: 26798647
BMJ. 2021 Jan 19;372:m4858
pubmed: 33468518
Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):723-732
pubmed: 27762640
Int J Technol Assess Health Care. 2005 Spring;21(2):240-5
pubmed: 15921065
Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):689-704
pubmed: 27805469
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
J Med Internet Res. 2018 Jun 08;20(6):e201
pubmed: 29884608
Annu Rev Public Health. 2015 Mar 18;36:483-505
pubmed: 25581147
J Med Internet Res. 2019 Jun 18;21(6):e12505
pubmed: 31215517
JMIR Mhealth Uhealth. 2020 Mar 27;8(3):e17776
pubmed: 32217503
Value Health. 2021 Apr;24(4):463-472
pubmed: 33840423
Front Nutr. 2022 Jun 24;9:915847
pubmed: 35811957
PLoS Med. 2022 Jul 21;19(7):e1004053
pubmed: 35862305
Diabetes Res Clin Pract. 2020 Apr;162:108084
pubmed: 32061819